Search research articles
Contact Us
Filters
Showing results (171-180 of 226) with videos related to
Page
of 23
Sort By:
Future Oncology (London, England)
|
December 17, 2019
First-line immune checkpoint inhibitor use in cisplatin-eligible patients with advanced urothelial carcinoma: a secular trend analysis
Ravi B Parikh, Emily K Feld, Matthew D Galsky, et al.
JCO Oncology Practice
|
August 5, 2024
Re-Envisioning Electronic Health Records to Optimize Patient-Centered Cancer Care, Quality, Surveillance, and Research
Aditi P Singh, Erin P Balogh, Robert W Carlson, et al.
Cancer Chemotherapy and Pharmacology
|
February 5, 2004
Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer
Steven J Cohen, James Gallo, Nancy L Lewis, et al.
American Journal of Clinical Oncology
|
October 7, 2006
Phase II trial of preoperative chemoradiation with a hyperfractionated radiation boost in locally advanced rectal cancer
Benjamin Movsas, Hasmik Diratzouian, Alexandra Hanlon, et al.
Journal of the National Cancer Institute
|
May 31, 2022
Digital Health Applications in Oncology: An Opportunity to Seize
Ravi B Parikh, Karen M Basen-Enquist, Cathy Bradley, et al.
Breast Cancer Research and Treatment
|
June 18, 2017
A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104)
Lori J Goldstein, Fengmin Zhao, Molin Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 17, 2003
Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant
Neal J Meropol, Robert A Somer, John Gutheil, et al.
International Journal of Radiation Oncology, Biology, Physics
|
July 22, 2011
Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer
Stuart J Wong, Kathryn Winter, Neal J Meropol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 10, 2008
Activity of sunitinib in patients with advanced neuroendocrine tumors
Matthew H Kulke, Heinz-Josef Lenz, Neal J Meropol, et al.
Cancer Biology & Therapy
|
November 23, 2007
Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancer
Kalyani Narra, Stefanie R Mullins, Hyung-Ok Lee, et al.
Page
of 23
Search research articles
Search
Showing results (171-180 of 226) with videos related to
Sort By:
Page
of 23
Future Oncology (London, England)
|
December 17, 2019
First-line immune checkpoint inhibitor use in cisplatin-eligible patients with advanced urothelial carcinoma: a secular trend analysis
Ravi B Parikh, Emily K Feld, Matthew D Galsky, et al.
JCO Oncology Practice
|
August 5, 2024
Re-Envisioning Electronic Health Records to Optimize Patient-Centered Cancer Care, Quality, Surveillance, and Research
Aditi P Singh, Erin P Balogh, Robert W Carlson, et al.
Cancer Chemotherapy and Pharmacology
|
February 5, 2004
Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer
Steven J Cohen, James Gallo, Nancy L Lewis, et al.
American Journal of Clinical Oncology
|
October 7, 2006
Phase II trial of preoperative chemoradiation with a hyperfractionated radiation boost in locally advanced rectal cancer
Benjamin Movsas, Hasmik Diratzouian, Alexandra Hanlon, et al.
Journal of the National Cancer Institute
|
May 31, 2022
Digital Health Applications in Oncology: An Opportunity to Seize
Ravi B Parikh, Karen M Basen-Enquist, Cathy Bradley, et al.
Breast Cancer Research and Treatment
|
June 18, 2017
A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104)
Lori J Goldstein, Fengmin Zhao, Molin Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 17, 2003
Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant
Neal J Meropol, Robert A Somer, John Gutheil, et al.
International Journal of Radiation Oncology, Biology, Physics
|
July 22, 2011
Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer
Stuart J Wong, Kathryn Winter, Neal J Meropol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 10, 2008
Activity of sunitinib in patients with advanced neuroendocrine tumors
Matthew H Kulke, Heinz-Josef Lenz, Neal J Meropol, et al.
Cancer Biology & Therapy
|
November 23, 2007
Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancer
Kalyani Narra, Stefanie R Mullins, Hyung-Ok Lee, et al.
Page
of 23